The UK biotech sector feels reassured by John Healey's appointment as Chancellor, not because of his known policies, but because he is not Ed Miliband. Industry leaders feared Miliband’s strong focus on "net zero" policies would divert investment and attention away from the life sciences, making this a classic case of relief from a perceived threat.
A stark economic divide exists in the UK's clinical research landscape. The South has costs comparable to the United States, while the North is significantly less expensive. Critically, an executive from a top global CRO confirms that the capabilities and quality in the North are just as strong as in the South or the US, presenting a major cost-saving opportunity for trial sponsors.
Unlike markets dominated by institutional investors, Taiwan's biotech ecosystem benefits from a strong base of local retail investors. These investors act as "local heroes," demonstrating remarkable loyalty by sticking with companies even after significant setbacks. This provides a unique source of stability and staying power, enabling companies to survive and eventually thrive through difficult periods.
Biogen is proceeding with its anti-tau therapy Duranderson, even though it missed its primary endpoint. The rationale is that the observed slowing of cognitive decline on secondary measures (26-50%) is comparable, or even slightly better than, the results of already-approved anti-amyloid antibodies. This strategy shows how a technically 'failed' trial can find a path forward by meeting the efficacy bar set by existing treatments.
The acting FDA Commissioner has vowed to abandon his predecessor's informal method of setting policy via podcasts and articles. However, this reversal was communicated not through official guidance, but in a private letter to a member of Congress. This leaves companies in a state of confusion, unsure which policies are officially active and which have been unofficially rescinded.
Senior FDA officials, both current and former, openly acknowledge that they select members for advisory committees (adcoms) who are likely to provide the results the agency desires. This practice of 'picking the jury' reveals a systemic bias, challenging the perception that adcoms are fully independent bodies and suggesting that the FDA has its 'finger on the scale' during these critical reviews.